Biosimilars in the Rest of the World: Developments in Lesser-Regulated Countries

by Ronald A. Rader
Volume 12, Issue 4 (Winter 2013/2014)

Biosimilars, and related biopharmaceutical biobetters and biogenerics, are still relatively new, but are already starting to impact worldwide biopharmaceutical markets. Most discussions of biosimilars center on developed regions where markets are mature and manufacturing capabilities allow for the cost-efficient manufacture of these complex molecules. This article covers the development of these products outside the United States (US), European Union (EU), and other developed, generally rather affluent and high-technology economy-based countries. To start, we first offer some definitions...

Citation:
Rader RA. Biosimilars in the Rest of the World: Developments in Lesser-Regulated Countries. BioProcess J, 2014; 12(4): 41-47. http://dx.doi.org/10.12665/J124.Rader.

Posted online January 13, 2014.